Spina bifida epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 27: | Line 27: | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
*Before 1960, the case-mortality rate of all forms of spina bifida was 90% to 88%.<ref name="pmid4937369">{{cite journal |vauthors=Lorber J |title=Results of treatment of myelomeningocele. An analysis of 524 unselected cases, with special reference to possible selection for treatment |journal=Dev Med Child Neurol |volume=13 |issue=3 |pages=279–303 |date=June 1971 |pmid=4937369 |doi= |url=}}</ref> | *Before 1960, the case-mortality rate of all forms of spina bifida was 90% to 88%.<ref name="pmid4937369">{{cite journal |vauthors=Lorber J |title=Results of treatment of myelomeningocele. An analysis of 524 unselected cases, with special reference to possible selection for treatment |journal=Dev Med Child Neurol |volume=13 |issue=3 |pages=279–303 |date=June 1971 |pmid=4937369 |doi= |url=}}</ref> | ||
*Now the mortality rate | *In all patients with neural tube defects including spina bifida: | ||
**Now the mortality rate is approximately is 10.1%. | |||
**The overall [[Ventriculoperitoneal shunt|ventriculoperitoneal]] shunt requirement rate is 33.8%. | |||
**[[Paraplegia]] rate is 30.7%. | |||
**The [[neurogenic bladder]] rate is 51.6%. | |||
**The [[infection]] rate is 6.4% after the surgical procedure. | |||
* | * | ||
Revision as of 15:13, 28 January 2019
|
Spina bifida Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Spina bifida epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Spina bifida epidemiology and demographics |
|
Risk calculators and risk factors for Spina bifida epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
Age
- Spina bifida is more commonly observed among preterm newborns.[1]
Gender
- Female newborns are more commonly affected with spina bifida than male newborns.[2]
Race
- Spina bifida usually affects individuals of the Malays and Chinese and Indians race.[3]
Epidemiology and Demographics
Incidence
The incidence of spina bifida is approximately 3.5 per 10,000 live births per year in the U.S.[4][5]
Prevalence
The prevalence of spina bifida is approximately 187 to 890 per 100,000 live births.[3]
Case-fatality rate/Mortality rate
- Before 1960, the case-mortality rate of all forms of spina bifida was 90% to 88%.[6]
- In all patients with neural tube defects including spina bifida:
- Now the mortality rate is approximately is 10.1%.
- The overall ventriculoperitoneal shunt requirement rate is 33.8%.
- Paraplegia rate is 30.7%.
- The neurogenic bladder rate is 51.6%.
- The infection rate is 6.4% after the surgical procedure.
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Bannur BB, Purandare GM (February 1969). "Microbial production of L-lysine". Hindustan Antibiot Bull. 11 (3): 191–205. PMID 4898641.
- ↑ Doutre MS, Beylot C, Busquet M, Barberis C, Fauchier JM, Lecastereyres D, Beylot J (April 1986). "[Familial scleroderma of the Thibierge-Weissenbach type]". Rev Rhum Mal Osteoartic (in French). 53 (4): 290–1. PMID 3738390.
- ↑ 3.0 3.1 Csaba G, Körösi J (1968). "A new antitumour agent: phenazathionium-mustard salt". Neoplasma. 15 (4): 443–5. PMID 5684468.
- ↑ Bass SW, Triolo AJ, Coon JM (August 1972). "Effect of DDT on the toxicity and metabolism of parathion in mice". Toxicol. Appl. Pharmacol. 22 (4): 684–93. PMID 5045772.
- ↑ Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins JS, Kirby RS, Correa A (December 2010). "Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006". Birth Defects Res. Part A Clin. Mol. Teratol. 88 (12): 1008–16. doi:10.1002/bdra.20735. PMID 20878909.
- ↑ Lorber J (June 1971). "Results of treatment of myelomeningocele. An analysis of 524 unselected cases, with special reference to possible selection for treatment". Dev Med Child Neurol. 13 (3): 279–303. PMID 4937369.